Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 376

1.

Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?

Kielstein JT, Zoccali C.

Am J Kidney Dis. 2005 Aug;46(2):186-202. Review.

PMID:
16112037
[PubMed - indexed for MEDLINE]
2.

Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease.

Mallamaci F, Zoccali C.

J Ren Nutr. 2009 Jan;19(1):25-8. doi: 10.1053/j.jrn.2008.10.013.

PMID:
19121766
[PubMed - indexed for MEDLINE]
3.

Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.

Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, ter Wee PM, van Guldener C.

Kidney Int. 2005 Nov;68(5):2230-6.

PMID:
16221223
[PubMed - indexed for MEDLINE]
4.

The past, presence and future of ADMA in nephrology.

Kielstein JT, Fliser D.

Nephrol Ther. 2007 Apr;3(2):47-54. Epub 2007 Apr 5. Review.

PMID:
17452300
[PubMed - indexed for MEDLINE]
5.

Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.

Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S.

Clin Exp Nephrol. 2007 Jun;11(2):115-21. Epub 2007 Jun 28. Review.

PMID:
17593510
[PubMed - indexed for MEDLINE]
6.

Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease.

Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Böger R; CREED Investigators.

J Am Soc Nephrol. 2002 Feb;13(2):490-6.

PMID:
11805179
[PubMed - indexed for MEDLINE]
Free Article
7.

Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease.

Mallamaci F, Tripepi G, Maas R, Malatino L, Böger R, Zoccali C.

J Am Soc Nephrol. 2004 Feb;15(2):435-41.

PMID:
14747391
[PubMed - indexed for MEDLINE]
Free Article
8.

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R.

Lancet. 2001 Dec 22-29;358(9299):2113-7.

PMID:
11784625
[PubMed - indexed for MEDLINE]
9.

Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.

Zoccali C.

Blood Purif. 2002;20(5):469-72.

PMID:
12207095
[PubMed - indexed for MEDLINE]
10.

Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.

Böger RH.

Vasc Med. 2005 Jul;10 Suppl 1:S19-25. Review.

PMID:
16444865
[PubMed - indexed for MEDLINE]
11.

Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move.

Zoccali C.

J Hypertens. 2006 Apr;24(4):611-9. Review.

PMID:
16531785
[PubMed - indexed for MEDLINE]
12.

ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.

Böger RH, Zoccali C.

Atheroscler Suppl. 2003 Dec;4(4):23-8. Review.

PMID:
14664899
[PubMed - indexed for MEDLINE]
13.

Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.

Kumagai H, Sakurai M, Takita T, Maruyama Y, Uno S, Ikegaya N, Kato A, Hishida A.

Am J Kidney Dis. 2006 Nov;48(5):797-805.

PMID:
17059999
[PubMed - indexed for MEDLINE]
14.

[Asymmetric dimethylarginine--a novel cardiovascular risk factor].

Siroká R, Cibulka R, Rajdl D, Racek J.

Vnitr Lek. 2006 Mar;52(3):249-55. Review. Czech.

PMID:
16722156
[PubMed - indexed for MEDLINE]
15.

Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.

Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Böger R; CREED Investigators.

Kidney Int. 2002 Jul;62(1):339-45.

PMID:
12081596
[PubMed - indexed for MEDLINE]
Free Article
16.

Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.

Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, Frölich JC.

J Am Soc Nephrol. 1999 Mar;10(3):594-600.

PMID:
10073610
[PubMed - indexed for MEDLINE]
Free Article
17.

Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease.

Kielstein JT, Bode-Böger SM, Frölich JC, Haller H, Böger RH.

Kidney Int Suppl. 2001 Feb;78:S9-13. Review.

PMID:
11168975
[PubMed - indexed for MEDLINE]
18.

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.

Böger RH.

Cardiovasc Res. 2003 Oct 1;59(4):824-33. Review.

PMID:
14553822
[PubMed - indexed for MEDLINE]
Free Article
19.

Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease.

van Guldener C, Nanayakkara PW, Stehouwer CD.

Clin Chem Lab Med. 2007;45(12):1683-7. Review.

PMID:
17937610
[PubMed - indexed for MEDLINE]
20.

Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography.

Furuki K, Adachi H, Enomoto M, Otsuka M, Fukami A, Kumagae S, Matsuoka H, Nanjo Y, Kakuma T, Imaizumi T.

Hypertens Res. 2008 Jun;31(6):1185-9. doi: 10.1291/hypres.31.1185.

PMID:
18716367
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk